{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-030851","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2023-04-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.365217+00:00","generated_at":"2026-06-16T23:35:21.914846+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"low","headline":"Relmada Therapeutics updates corporate presentation, no financial data disclosed","bullets":["Filed 8-K on April 19, 2023, to announce an updated corporate presentation.","Presentation titled 'Targeting Major Advances in the Treatment of CNS Disorders' filed as Exhibit 99.1.","No specific financial or operational milestones provided in the filing or exhibit text.","CEO Sergio Traversa signed the filing; presentation may contain pipeline or strategy updates."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-030851","json":"https://secwatch.observer/filing/0001213900-23-030851.json","markdown":"https://secwatch.observer/filing/0001213900-23-030851.md","text":"https://secwatch.observer/filing/0001213900-23-030851.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023030851/0001213900-23-030851-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023030851/ea177149-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T23:35:21.914846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}